Christine Hogan, MD

Assistant Professor

view physician profile

Locations

Froedtert Hospital
Vivent Health

Specialties

Infectious Disease

Languages

English

Vivent Health

(414) 223-6800

Education

MD - Doctor of Medicine

Biography

Dr. Hogan joined the Department of Internal Medicine, Division of Infectious Diseases, at the Medical College of Wisconsin as an Assistant Professor in March 2008. She received her MD from the University of California, San Francisco School of Medicine in 1995. She subsequently completed a residency in Internal Medicine/Primary Care at Massachusetts General Hospital in Boston, Massachusetts in 1998, and a three year fellowship in Infectious Diseases at Columbia University Medical Center in New York City in 2001. She is board certified in Infectious Diseases and Internal Medicine.

Dr. Hogan relocated to Milwaukee and joined the faculty in 2008 and her primary role has been providing comprehensive and compassionate specialty and primary care to HIV-infected individuals at the AIDS Resource Center of Wisconsin. She is a member of The Infectious Disease Society of America, the HIV Medical Association, the American Academy of HIV Medicine, the American College of Physicians, and Alpha Omega Alpha.

Research Interests

Dr. Hogan began her career after fellowship at the Aaron Diamond AIDS Research Center at the Rockefeller University in New York in 2001 where she was involved in clinical and translational research with respect to acute and early HIV infection. She chaired a multi center clinical trial through the Adult AIDS Clinical Trials Group entitled "The Setpoint Study" which examined the effect of a finite period of antiretroviral treatment on subsequent virologic control in persons with newly acquired HIV infection. She also precepted fellows and practiced at Columbia University Medical Center.

The setpoint study (ACTG A5217): effect of immediate versus deferred antiretroviral therapy on virologic set point in recently HIV-1-infected individuals.

(Hogan CM, Degruttola V, Sun X, Fiscus SA, Del Rio C, Hare CB, Markowitz M, Connick E, Macatangay B, Tashima KT, Kallungal B, Camp R, Morton T, Daar ES, Little S, A5217 Study Team.) J Infect Dis. 2012 Jan 01;205(1):87-96 PMID: 22180621 PMCID: PMC3242744 12/20/2011
The virologic and immunologic effects of cyclosporine as an adjunct to antiretroviral therapy in patients treated during acute and early HIV-1 infection.

(Markowitz M, Vaida F, Hare CB, Boden D, Mohri H, Hecht FM, Kalayjian RC, Conrad A, Mildvan D, Aberg J, Hogan C, Kilby JM, Balfour HH Jr, Schafer K, Richman D, Little S.) J Infect Dis. 2010 May 01;201(9):1298-302 PMID: 20235838 PMCID: PMC2851487 03/20/2010
Robust analysis of biomarker data with informative missingness using a two-stage hypothesis test in an HIV treatment interruption trial: AIEDRP AIN503/ACTG A5217.

(Messer K, Vaida F, Hogan C.) Contemp Clin Trials. 2006 Dec;27(6):506-17 PMID: 16962381 09/12/2006
Tracking the prevalence of transmitted antiretroviral drug-resistant HIV-1: a decade of experience.

(Shet A, Berry L, Mohri H, Mehandru S, Chung C, Kim A, Jean-Pierre P, Hogan C, Simon V, Boden D, Markowitz M.) J Acquir Immune Defic Syndr. 2006 Apr 01;41(4):439-46 PMID: 16652051 05/03/2006
Neutralization profiles of newly transmitted human immunodeficiency virus type 1 by monoclonal antibodies 2G12, 2F5, and 4E10.

(Mehandru S, Wrin T, Galovich J, Stiegler G, Vcelar B, Hurley A, Hogan C, Vasan S, Katinger H, Petropoulos CJ, Markowitz M.) J Virol. 2004 Dec;78(24):14039-42 PMID: 15564511 PMCID: PMC533925 11/27/2004
Dynamics of intermittent viremia during highly active antiretroviral therapy in patients who initiate therapy during chronic versus acute and early human immunodeficiency virus type 1 infection.

(Di Mascio M, Markowitz M, Louie M, Hurley A, Hogan C, Simon V, Follmann D, Ho DD, Perelson AS.) J Virol. 2004 Oct;78(19):10566-73 PMID: 15367623 PMCID: PMC516378 09/16/2004
Primary HIV-1 infection is associated with preferential depletion of CD4+ T lymphocytes from effector sites in the gastrointestinal tract.

(Mehandru S, Poles MA, Tenner-Racz K, Horowitz A, Hurley A, Hogan C, Boden D, Racz P, Markowitz M.) J Exp Med. 2004 Sep 20;200(6):761-70 PMID: 15365095 PMCID: PMC2211967 09/15/2004
Viral blip dynamics during highly active antiretroviral therapy.

(Di Mascio M, Markowitz M, Louie M, Hogan C, Hurley A, Chung C, Ho DD, Perelson AS.) J Virol. 2003 Nov;77(22):12165-72 PMID: 14581553 PMCID: PMC253757 10/29/2003
Determining the antiviral activity of tenofovir disoproxil fumarate in treatment-naive chronically HIV-1-infected individuals.

(Louie M, Hogan C, Hurley A, Simon V, Chung C, Padte N, Lamy P, Flaherty J, Coakley D, Di Mascio M, Perelson AS, Markowitz M.) AIDS. 2003 May 23;17(8):1151-6 PMID: 12819516 06/24/2003
Determining the relative efficacy of highly active antiretroviral therapy.

(Louie M, Hogan C, Di Mascio M, Hurley A, Simon V, Rooney J, Ruiz N, Brun S, Sun E, Perelson AS, Ho DD, Markowitz M.) J Infect Dis. 2003 Mar 15;187(6):896-900 PMID: 12660935 03/28/2003
Host determinants in HIV infection and disease. Part 2: genetic factors and implications for antiretroviral therapeutics.

(Hogan CM, Hammer SM.) Ann Intern Med. 2001 May 15;134(10):978-96 PMID: 11352699 05/16/2001
Host determinants in HIV infection and disease. Part 1: cellular and humoral immune responses.

(Hogan CM, Hammer SM.) Ann Intern Med. 2001 May 01;134(9 Pt 1):761-76 PMID: 11329234 05/01/2001